FY2025 · ended Dec 31, 2025 · Revenue $13.79M, -12.2% YoY · Filed Mar 26, 2026
CV Sciences, Inc. (CVSI) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $13.8 million and a net loss of $958,000. Free cash flow was -$516,000. As of Jun 30, 2026 it held $266,000 in cash and investments and $236,000 in total debt.
Revenue (TTM)
$12.74M
-14.9% vs year-ago TTM
Net income (TTM)
$-2.01M
-29.3% vs year-ago TTM
Operating cash flow (TTM)
$-492,000
-515.0% vs year-ago TTM
Free cash flow (TTM)
$-522,000
EPS (TTM)
$-0.01
-24.0% vs year-ago TTM
Dividend per share
None
Shares outstanding
193.46M
+5.0% vs prior year
Net cash
$30,000
as of Jun 30, 2026
Operating margin
-7.6%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CVSI (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1510964
- Former names
- CannaVEST Corp. (until Jan 4, 2016); Foreclosure Solutions, Inc. (until Nov 30, 2012)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $13.8M | $15.7M | $16.0M | $16.2M | $20.0M |
| Operating income | -$470,000 | -$2.2M | $3.4M | -$6.8M | -$18.4M |
| Net income | -$958,000 | -$2.4M | $3.1M | -$8.2M | -$15.6M |
| Diluted EPS | -$0.01 | -$0.01 | $0.02 | -$0.07 | -$0.14 |
| Operating cash flow | -$407,000 | -$861,000 | $2.3M | -$1.9M | -$7.5M |
| Free cash flow | -$516,000 | -$879,000 | — | -$1.9M | -$7.5M |
| Total assets | $7.0M | $7.9M | $9.2M | $12.7M | $18.1M |
| Total liabilities | $5.5M | $6.1M | $6.3M | $13.5M | $14.5M |
| Stockholders' equity | $1.5M | $1.8M | $2.9M | -$777,000 | $3.5M |
| Cash and investments | $278,000 | $454,000 | $1.3M | — | $1.4M |
| Total debt | $2.0M | $102,000 | $188,000 | $305,000 | $310,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Oct 26, 2026 | Oct 23, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations, Other events
|
Aug 13, 2026 | May 14, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jun 4, 2026 | Mar 27, 2025 |
| 10-Q | Quarterly report | May 15, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
May 14, 2026 | May 14, 2026 |
All 431 CV Sciences, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.